CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 25 enrolled
Drug / intervention
2 mg Melatonin +2 moredrug
Likely dose
2 mg Melatoninfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02415309
NCT02415309Phase 3Completed

Premedication With Melatonin vs. Placebo in Patients Undergoing Interventional Pain Procedure

United States Naval Medical Center, San Diego·interventional·Posted Apr 14, 2015·Updated May 14, 2024

In Brief

A Phase 3 clinical trial evaluating 2 mg Melatonin, 10mg Melatonin, and 1 other intervention for Anxiety. Completed, enrolled 25 participants across 2 sites.

Detailed Summary

Lumbar medial branch blocks are commonly used as a diagnostic tool for facet-mediated chronic low back pain. This interventional pain procedure often occurs in the fluoroscopy suite. During this procedure, a physician inserts the needles to deliver local anesthetics such as lidocaine or bupivacaine to the nerves which innervate the lumbar facet joint. Many patients experience anxiety before and during the lumbar medial branch block procedure and require intravenous midazolam or fentanyl for sedation. Intravenous or conscious sedation requires one-to-one nursing care, monitoring, and recovery. In order to minimize the costs and time requirements of intravenous sedation, a suitable oral medication which is readily available and non-controlled would be ideal. Several randomized double-blinded, controlled trials have investigated the anxiolytic effects of melatonin before a surgery; however no studies to date have studied the anxiolytic effects of melatonin before less invasive interventional pain procedures. This study is designed to evaluate the efficacy of melatonin for reducing anxiety in patients undergoing a lumbar medial branch block procedure. The study is a randomized, double-blinded, placebo-controlled trial with 40 patients in each group: 2 mg melatonin, 10 mg melatonin and placebo. The primary outcome is anxiety reduction in patients before undergoing the procedure. The primary outcome is measured by visual numerical rating scale for anxiety and the Amsterdam Preoperative Anxiety and Information Scale. Based on the results of previous studies, the investigators hypothesize that melatonin may reduce anxiety in patients undergoing the procedure and be a suitable alternative to intravenous sedation in the pain clinic for patients undergoing lumbar medial branch blocks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnxiety
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 14, 2015
Enrollment StartJul 1, 2016
Primary CompletionMay 1, 2022
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 11.2 years ago

Interventions

2 mg Melatonindrug

40 patients will randomly receive 2 mg melatonin

10mg Melatonindrug

40 patients will randomly receive 10 mg melatonin

Placeboother

40 patients will randomly receive a placebo/sugar pill